Taken together, these results suggest that density patterns of different immune cell markers (namely CD3, CD4, CD8, CD20, CD57, CD68, and CD163) could be used to predict the prognosis of patients with cervical cancer and aid in evaluating the effectiveness of adjuvant chemoradiotherapy. This evidence concerns the gene CD68 and cervical cancer.